Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
IBB vs RSP: how they differ
IBB and RSP hold 2% of their weight in the same names, and IBB returned more over the year.
iShares Biotechnology ETF and Invesco S&P 500 Equal Weight ETF.
What they hold in common
By the books each fund has filed, IBB and RSP hold 2% of their money in the same securities at the same weight.
| Holding | IBB | RSP |
|---|---|---|
| Bio-Techne Corp. | 0.86% | 0.20% |
| Incyte Corp. | 1.75% | 0.19% |
| Biogen, Inc. | 2.47% | 0.19% |
| Charles River Laboratories International | 0.84% | 0.19% |
| Amgen, Inc. | 7.84% | 0.18% |
| Regeneron Pharmaceuticals, Inc. | 4.91% | 0.18% |
| Gilead Sciences, Inc. | 6.85% | 0.17% |
| Vertex Pharmaceuticals, Inc. | 8.09% | 0.17% |
| Moderna, Inc. | 1.99% | 0.16% |
| Only in IBB | Only in RSP |
|---|---|
| Argenx SE 3.76% | Intel Corp. 0.38% |
| Alnylam Pharmaceuticals, Inc. 3.12% | Seagate Technology Holdings PLC 0.34% |
| Natera, Inc. 2.89% | Advanced Micro Devices, Inc. 0.33% |
| Revolution Medicines, Inc. 2.78% | ON Semiconductor Corp. 0.33% |
| Illumina, Inc. 2.07% | Sandisk Corp. 0.32% |
| Insmed, Inc. 1.79% | Western Digital Corp. 0.31% |
| BeOne Medicines Ltd. 1.77% | Ciena Corp. 0.30% |
| United Therapeutics Corp. 1.74% | Monolithic Power Systems, Inc. 0.29% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Jun 30, 2026.
| IBB iShares Biotechnology ETF | RSP Invesco S&P 500 Equal Weight ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | Invesco |
| What it is | Biotechnology | S&P 500 equal weight |
| Total return, 1 year | +41.5% | +14.8% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +24.0 pts | −2.7 pts |
| Expense ratio | 0.44% | 0.20% |
| Already in the S&P 500 | 35.6% | 99.1% |
| Holdings | 248 | 503 |
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
RSP in plain words
RSP is an index equity fund tracking the S&P 500 equal weight. Over the year to Sep 11, 2026 it returned +14.8% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.20% a year. By its holdings filed for Apr 30, 2026, 99% of the fund by weight is stocks the S&P 500 also holds, across 503 positions, with the top ten at 3.2%. It sat 3.5% below its high of Aug 14, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, IBB or RSP?
- In the year to Sep 12, 2026, with distributions reinvested, IBB returned +41.5% and RSP returned +14.8%, so IBB returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, IBB or RSP?
- IBB charges 0.44% a year and RSP charges 0.20%, so RSP is cheaper. Fees come from each fund's prospectus.
- How much do IBB and RSP overlap with the S&P 500?
- By their latest filed holdings, 36% of IBB and 99% of RSP by weight is stocks the S&P 500 already holds. Between the two funds, 2% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, IBB against RSP, data as of Sep 12, 2026. https://etfiq.com/compare/any/IBB-RSP Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources